Design and analysis of phase II cancer trials: A review of statistical methods and guidelines for medical researchers

International Statistical Review

Volumn 64, Issue 1, 1996, Pages 61-88

  Mariani, L ^a,c   Marubini, E ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NONE   (Italy)

Author keywords

Binary outcomes; Cancer chemotherapy; Clinical research; Phase II trials; Sample size

Indexed keywords

EID: 0030557614     PISSN: 03067734     EISSN: None     Source Type: Journal    
DOI: 10.2307/1403424     Document Type: Review

References (38)

1. Aroian, L.A. (1968). Sequential analysis, direct method. Technometrics, 10, 125-132.
2. Atkinson, E.N., Brown, B.W. & Herson, J. (1982). KSTAGE: an interactive computer program for designing phase II clinical trials using predictive probability. Computers Biomed. Res., 15, 220-227.
3. Atkinson, E.N. & Brown, B.W. (1985). Confidence limits for probability of response in multistage phase II clinical trials. Biometrics, 41, 741-744.
4. Bellissant, E., Benichou, J. & Chastang, C. (1990). Application of the triangular test to phase II cancer clinical trials. Statist. Med., 9, 907-917.
5. Bossi, A. & Marubini, E. (1986). Procedure decisionali a due stadi per l'arresto di una sperimentazione clinica controllata. Rivista di Statistica Applicata, 19, 363-371.
6. Brunier, H.C. & Whitehead, J. (1992). Sample sizes for phase II clinical trials derived from Bayesian decision theory. In Proceedings of the International Society of Clinical Biostatistics Meeting, August 1992, Copenhagen.
7. Chang, M.N., Therneau, T.M., Wieand, H.S. & Cha, S.S. (1987). Designs for group sequential phase II clinical trials. Biometrics, 43, 865-874.
8. Chen, S., Soong, S. & Wheeler, R. H. (1994). An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectives. Controlled Clin. Trials, 15, 277-283.
9. Clopper, C.J. & Pearson, E.S. (1934). The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika, 26, 404-413.
10. Ellenberg, S.S. & Eisenberger M.A. (1985). An efficient design for phase III studies of combination chemotherapies. Cancer Treat Rep., 69, 1147-1154.
11. Ensign L.G., Gehan E.A., Kamen D.S. & Thall, P.F. (1994). An optimal three-stage design for phase II clinical trials. Statist. Med., 13, 1727-1736.
12. Fleiss J.L. (1981). Statistical Methods for Rates and Proportions. New York: Wiley.
13. Fleming T.R. (1982). One-sample multiple testing procedure for phase II clinical trials. Biometrics, 38, 143-151.
14. Gehan E.A. (1961). The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chron. Dis., 13, 346-353.
15. Ghosh B.K. (1970). Sequential Tests of Statistical Hypotheses. Reading MA: Addison-Wesley.
16. Herson J. (1979). Predictive probability early termination plans for phase II clinical trials. Biometrics, 35, 775-783.
17. Herson J. (1980). Patient registration in a cooperative oncology group. Controlled Clin. Trials, 1, 101-110.
18. Herson J. & Carter S.K. (1986). Calibrated phase II clinical trials in oncology. Statist. Med. 5, 441-447.
19. Hilden J. (1990). Corrected loss calculation for phase II trials. Biometrics, 46, 535-538.
20. Hilsenbeck G.S. (1988). Early termination of a phase II clinical trial. Controlled Clin. Trials, 9, 177-188.
21. Lee Y.J., Staquet M., Simon R. et al. (1979). Two-stage plans for patient accrual in phase II cancer clinical trials. Cancer Treat. Rep., 63, 1721-1726.
22. Marsoni S., Hoth D., Simon R. et al. (1987). Clinical drug development: an analysis of phase II trials, 1970-1985. Cancer Treat. Rep., 71, 71-80.
23. Mehta C.R. & Caine K.C. (1984). Charts for the early stopping of pilot studies. J. Clin. Oncol. 2, 676-682.
24. O'Brien P.C. & Fleming T.R. (1979). A multiple testing procedure for clinical trials. Biometrics, 35, 549-556.
25. Oken M.M., Creech R. H., Tormey D. C. et al. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649-655.
26. Schultz J.R., Nichol F.R., Elfring G.L. & Weed S.D. (1973). Multiple-stage procedures for drug screening. Biometrics, 29, 293-300.
27. Simon R. (1987). How large should a phase II trial be? Cancer Treat. Rep., 71, 1079-1085.
28. Simon R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clin. Trials, 10, 1-10.
29. Simon R., Thall, P.F. & Ellenherg S.S. (1994). New designs for the selection of treatments to be tested in randomized clinical trials. Statist. Med. 13, 417-429.
30. Storer B.E. (1992). A class of phase II designs with three possible outcomes. Biometrics, 48, 55-60.
31. Sylvester R.J. & Staquet M.J. (1977). An application of decision theory to phase II clinical trials in cancer. In Recent Advances in Cancer Treatment, Eds. Tagnon, H.J. & Staquet, M.J. New York: Raven Press.
32. Sylvester R.J. & Staquet M.J. (1980). Design of phase II clinical trials in cancer using decision theory. Cancer Treat. Rep. 64, 519-524.
33. Sylvester R.J. (1988). A Bayesian approach to the design of phase II clinical trials. Biometrics, 44, 823-836.
34. Thall P.F. & Simon, R. (1990). Incorporating historical control data in planning phase II clinical trials. Statist. Med. 9, 215-228.
35. Thall P.F. & Simon R. (1994). Practical Bayesian guidelines for phase IIb clinical trials. Biometrics, 50, 337-349.
36. Wald, A. (1947). Sequential Analysis. New York:Wiley.
37. Whitehead, J. (1983). The Design and Analysis of Sequential Clinical Trials. Chichester: Ellis Horwood.
38. Wieand, S. & Therneau, T. (1987). A two-stage design for randomized trials with binary outcomes. Controlled Clin. Trials, 8, 20-28.